

RNS Number : 3187L  
Diaceutics PLC  
05 September 2023

## Notice of Interim Results and Presentations

**Belfast and London, 5 September 2023 - Diaceutics PLC (AIM: DXRX)** a leading technology and solutions provider to the pharmaceutical industry, today confirms that it will announce its unaudited results for the six months ended 30 June 2023 on Tuesday, 26 September 2023.

### Analyst Presentation

A webinar presentation for analysts will be held at 10.00am on Tuesday, 26 September 2023 via the London Stock Exchange's SparkLive platform. Those wishing to attend can register using the following link:

<https://www.lsegissuerservices.com/spark/Diaceutics/events/3e138a9b-2f9d-4adf-b5e0-790cb1f39b49>

### Investor Presentation

Peter Keeling (CEO), Nick Roberts (CFO) and Ryan Keeling (CIO) will also provide a live presentation relating to the Company's results via the Investor Meet Company platform on Tuesday 26 September 2023 at 4.30pm.

The presentation is open to all existing and potential shareholders and registration can be completed via the following link:

<https://www.investormeetcompany.com/diaceutics-plc/register-investor>

Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00am the day before the meeting or at any time during the live presentation. Investors who already follow Diaceutics on the Investor Meet Company platform will automatically be invited.

### Enquiries:

#### Diaceutics PLC

Peter Keeling, Chief Executive Officer  
Ryan Keeling, Chief Innovation Officer  
Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500  
[investorrelations@diaceutics.com](mailto:investorrelations@diaceutics.com)

#### Stifel Nicolaus Europe Limited (Nomad & Broker)

Ben Maddison  
Nick Harland  
Kate Hanshaw

Tel: +44 (0)20 7710 7600

#### Alma PR

Caroline Forde  
Matthew Young  
Kinvara Verdon

Tel: +44(0)20 3405 0205  
[diaceutics@almapr.co.uk](mailto:diaceutics@almapr.co.uk)

### About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by our proprietary DXRX platform.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORUPUWABUPWGWC